Yoon Seok Suh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yoon Seok Suh has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Ho Kyung Seo
Department of Urology, Center for Urologic Cancer, National Cancer Center, Goyang, Korea
2 shared publications - Jae Young Joung
Department of Urology, Urological Cancer Center, National Cancer Center, Goyang 10408, Republic of Korea
2 shared publications - Gyu Ha Ryu
Department of Medical Device Management and Research, SAIHST, Sungkyunkwan University, Seoul, Korea
1 shared publication H.K. Seo
1 shared publication- Hye Sup Yun
Department of Biological Sciences, Konkuk University, Seoul, Korea
1 shared publication - Hyun Hwan Sung
Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
1 shared publication
Latest Publications
- Open Access
- 5 November 2017
- Published by Wiley in BioMed Research International
- Vol. 2017, 1-9
Establishment and Application of Prostate Cancer Circulating Tumor Cells in the Era of Precision Medicine
Prostate cancer (PC) is the second most common cancer in men and is the fifth leading cause of cancer-related deaths worldwide. Additionally, there is concern for overdiagnosis and overtreatment of PC. Thus, selection of an appropriate candidate for active surveillance as well as more accurate and less invasive tools for monitoring advanced PC is required. Circulating tumor cells (CTCs) have emerged as a liquid biopsy tool; there have been several reports on its role, technologies, and applications to various cancers, including PC. Liquid biopsy using CTCs has been gaining attention as a minimal invasive tool for investigation of biomarkers and for prognosis and assessment of response to therapies in patients with PC. Because of the lower invasiveness of liquid biopsy using CTCs, it can be performed more frequently; accordingly, personalized disease status can be successively determined at serial time points. CTC analysis enables detection of genomic alterations, which is drug-targetable, and it is a potential tool for monitoring response to therapeutic agents in patients with PC. This review focuses on the characteristics, technologies for analysis, and advantages and disadvantages of CTCs as a liquid biopsy tool and their application in PC. Finally, we propose future directions of CTCs.
- 5 November 2017
- Published by Wiley in BioMed Research International
- Vol. 2017, 1-9
Open AccessEstablishment and Application of Prostate Cancer Circulating Tumor Cells in the Era of Precision Medicine
Prostate cancer (PC) is the second most common cancer in men and is the fifth leading cause of cancer-related deaths worldwide. Additionally, there is concern for overdiagnosis and overtreatment of PC. Thus, selection of an appropriate candidate for active surveillance as well as more accurate and less invasive tools for monitoring advanced PC is required. Circulating tumor cells (CTCs) have emerged as a liquid biopsy tool; there have been several reports on its role, technologies, and applications to various cancers, including PC. Liquid biopsy using CTCs has been gaining attention as a minimal invasive tool for investigation of biomarkers and for prognosis and assessment of response to therapies in patients with PC. Because of the lower invasiveness of liquid biopsy using CTCs, it can be performed more frequently; accordingly, personalized disease status can be successively determined at serial time points. CTC analysis enables detection of genomic alterations, which is drug-targetable, and it is a potential tool for monitoring response to therapeutic agents in patients with PC. This review focuses on the characteristics, technologies for analysis, and advantages and disadvantages of CTCs as a liquid biopsy tool and their application in PC. Finally, we propose future directions of CTCs.
- 1 September 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (6) , e2315
Comparison of lymph node yield during robot-assisted laparoscopic prostatectomy with that in radical retropubic prostatectomy in patients with high-risk prostate cancer
- 1 September 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (6) , e2315
Comparison of lymph node yield during robot-assisted laparoscopic prostatectomy with that in radical retropubic prostatectomy in patients with high-risk prostate cancer
- 1 June 2017
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 6 (S4) , S733-S743
Establishment and application of bladder cancer patient-derived xenografts as a novel preclinical platform
The prognosis and treatment of bladder cancer have hardly improved in the last 20 years, with the exception of immunotherapy using a PD-1/PD-L1 blocker, which was approved by the United States Food and Drug Administration in 2016. Hence, bladder cancer remains a debilitating and often fatal disease, and among one of the costliest cancers to treat. Preclinical models that are more representative of human cancer are urgently needed to improve our understanding of bladder cancer progression, as well as advance its diagnosis and treatment. Patient-derived xenografts (PDXs), involving the transfer of tumor fragments from individual patients into immunocompromised animals such as severe combined immunodeficient or nude mice, have been developed and utilized as a preclinical model of bladder cancer. PDX models recapitulating clinical behavior, including the drug response of several cancers, have demonstrated high predictive capacity to test standard chemotherapy regimens and to identify tumor types that might benefit from new treatments in clinical trials. However, current PDX models have limitations to their translation into current clinical trials including PD-1/PD-L1-related trials and personalized medicine. This review focuses on the advantages and disadvantages of PDX models in drug development, their application in bladder cancer, and future directions of PDX models.
- 1 June 2017
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 6 (S4) , S733-S743
Establishment and application of bladder cancer patient-derived xenografts as a novel preclinical platform
The prognosis and treatment of bladder cancer have hardly improved in the last 20 years, with the exception of immunotherapy using a PD-1/PD-L1 blocker, which was approved by the United States Food and Drug Administration in 2016. Hence, bladder cancer remains a debilitating and often fatal disease, and among one of the costliest cancers to treat. Preclinical models that are more representative of human cancer are urgently needed to improve our understanding of bladder cancer progression, as well as advance its diagnosis and treatment. Patient-derived xenografts (PDXs), involving the transfer of tumor fragments from individual patients into immunocompromised animals such as severe combined immunodeficient or nude mice, have been developed and utilized as a preclinical model of bladder cancer. PDX models recapitulating clinical behavior, including the drug response of several cancers, have demonstrated high predictive capacity to test standard chemotherapy regimens and to identify tumor types that might benefit from new treatments in clinical trials. However, current PDX models have limitations to their translation into current clinical trials including PD-1/PD-L1-related trials and personalized medicine. This review focuses on the advantages and disadvantages of PDX models in drug development, their application in bladder cancer, and future directions of PDX models.
- Open Access
- 15 April 2017
- Published by Taylor & Francis in Animal Cells and Systems
- Vol. 21 (3) , 160-168
Phenotypic differences betweenDrosophilaAlzheimer’s disease models expressing humanAβ42in the developing eye and brain
Drosophila melanogaster expressing amyloid-β42 (Aβ42) transgenes have been used as models to study Alzheimer’s disease. Various Aβ42 transgenes with different structures induce different phenotypes, which make it difficult to compare data among studies which use different transgenic lines. In this study, we compared the phenotypes of four frequently used Aβ42 transgenic lines, UAS-Aβ422X, UAS-Aβ42BL33770, UAS-Aβ4211C39, and UAS-Aβ42H29.3. Among the four transgenic lines, only UAS-Aβ422X has two copies of the upstream activation sequence-amyloid-β42 (UAS-Aβ42) transgene, while remaining three have one copy. UAS-Aβ42BL33770 has the 3′ untranslated region of Drosophila α-tubulin, while the others have that of SV40. UAS-Aβ4211C39 and UAS-Aβ42H29.3 have the rat pre-proenkephalin signal peptide, while UAS-Aβ422X and UAS-Aβ42BL33770 have that of the fly argos protein. When the transgenes were expressed ectopically in the developing eyes of the flies, UAS-Aβ422X transgene resulted in a strongly reduced and rough eye phenotype, while UAS-Aβ42BL33770 only showed a strong rough eye phenotype; UAS-Aβ42H29.3 and UAS-Aβ4211C39 had mild rough eyes. The levels of cell death and reactive oxygen species (ROS) in the eye imaginal discs were consistently the highest in UAS-Aβ422X, followed by UAS-Aβ42BL33770, UAS-Aβ4211C39, and UAS-Aβ42H29.3. Surprisingly, the reduction in survival during the development of these lines did not correlate with cell death or ROS levels. The flies which expressed UAS-Aβ4211C39 or UAS-Aβ42H29.3 experienced greatly reduced survival rates, although low levels of ROS or cell death were detected. Collectively, our results demonstrated that different Drosophila AD models show different phenotypic severity, and suggested that different transgenes may have different modes of cytotoxicity. Abbreviations: Aβ42: amyloid-β42; AD: Alzheimer’s disease; UAS: upstream activation sequence
- 15 April 2017
- Published by Taylor & Francis in Animal Cells and Systems
- Vol. 21 (3) , 160-168
Open AccessPhenotypic differences betweenDrosophilaAlzheimer’s disease models expressing humanAβ42in the developing eye and brain
Drosophila melanogaster expressing amyloid-β42 (Aβ42) transgenes have been used as models to study Alzheimer’s disease. Various Aβ42 transgenes with different structures induce different phenotypes, which make it difficult to compare data among studies which use different transgenic lines. In this study, we compared the phenotypes of four frequently used Aβ42 transgenic lines, UAS-Aβ422X, UAS-Aβ42BL33770, UAS-Aβ4211C39, and UAS-Aβ42H29.3. Among the four transgenic lines, only UAS-Aβ422X has two copies of the upstream activation sequence-amyloid-β42 (UAS-Aβ42) transgene, while remaining three have one copy. UAS-Aβ42BL33770 has the 3′ untranslated region of Drosophila α-tubulin, while the others have that of SV40. UAS-Aβ4211C39 and UAS-Aβ42H29.3 have the rat pre-proenkephalin signal peptide, while UAS-Aβ422X and UAS-Aβ42BL33770 have that of the fly argos protein. When the transgenes were expressed ectopically in the developing eyes of the flies, UAS-Aβ422X transgene resulted in a strongly reduced and rough eye phenotype, while UAS-Aβ42BL33770 only showed a strong rough eye phenotype; UAS-Aβ42H29.3 and UAS-Aβ4211C39 had mild rough eyes. The levels of cell death and reactive oxygen species (ROS) in the eye imaginal discs were consistently the highest in UAS-Aβ422X, followed by UAS-Aβ42BL33770, UAS-Aβ4211C39, and UAS-Aβ42H29.3. Surprisingly, the reduction in survival during the development of these lines did not correlate with cell death or ROS levels. The flies which expressed UAS-Aβ4211C39 or UAS-Aβ42H29.3 experienced greatly reduced survival rates, although low levels of ROS or cell death were detected. Collectively, our results demonstrated that different Drosophila AD models show different phenotypic severity, and suggested that different transgenes may have different modes of cytotoxicity. Abbreviations: Aβ42: amyloid-β42; AD: Alzheimer’s disease; UAS: upstream activation sequence
- Open Access
- 31 March 2017
- Published by Korean Continence Society in International Neurourology Journal
- Vol. 21 (1) , 68-74
Surgical Outcomes and Safety of Robotic Sacrocolpopexy in Women With Apical Pelvic Organ Prolapse
This study aimed to investigate the surgical outcomes and safety of robotic sacrocolpopexy (RSC) in patients with uterine/vaginal vault prolapse. Between January 2009 and June 2015, 16 women with apical prolapse underwent RSC. Pelvic organ prolapse quantification (POP-Q) examination was performed, and treatment success was defined as the presence of grade 0 or I apical prolapse upon POP-Q examination at the final follow-up. Pelvic floor distress inventory-short form 20 (PFDI-SF 20) was administered at every follow-up. A treatment satisfaction questionnaire was administered by telephone to evaluate patient satisfaction with the operation. Median age was 65 years (interquartile range [IQR], 56-68 years), and follow-up duration was 25.3 months (IQR, 5.4-34.0 months). Thirteen women (81.3%) had ≥grade III apical prolapse. Operation time was 251 minutes (IQR, 236-288 minutes), and blood loss was 75 mL (IQR, 50-150 mL). Median hospital stay was 4 days (IQR, 3-5 days). At the final follow-up, treatment success was reported in all patients, who presented grade 0 (n=8, 57.1%) and grade I (n=6, 42.9%) apical prolapse. Dramatic improvements in PFDI-SF 20 scores were noted after RSC (from 39 to 4; P=0.001). Most patients (12 of 13) were satisfied with RSC. An intraoperative complication (sacral venous plexus injury) was reported in 1 patient, and there was no conversion to open surgery. Mesh erosion was not reported. RSC is an efficient and safe surgical option for apical prolapse repair. Most patients were satisfied with RSC. Thus, RSC might be one of the best treatment options for apical prolapse in women.
- 31 March 2017
- Published by Korean Continence Society in International Neurourology Journal
- Vol. 21 (1) , 68-74
Open AccessSurgical Outcomes and Safety of Robotic Sacrocolpopexy in Women With Apical Pelvic Organ Prolapse
This study aimed to investigate the surgical outcomes and safety of robotic sacrocolpopexy (RSC) in patients with uterine/vaginal vault prolapse. Between January 2009 and June 2015, 16 women with apical prolapse underwent RSC. Pelvic organ prolapse quantification (POP-Q) examination was performed, and treatment success was defined as the presence of grade 0 or I apical prolapse upon POP-Q examination at the final follow-up. Pelvic floor distress inventory-short form 20 (PFDI-SF 20) was administered at every follow-up. A treatment satisfaction questionnaire was administered by telephone to evaluate patient satisfaction with the operation. Median age was 65 years (interquartile range [IQR], 56-68 years), and follow-up duration was 25.3 months (IQR, 5.4-34.0 months). Thirteen women (81.3%) had ≥grade III apical prolapse. Operation time was 251 minutes (IQR, 236-288 minutes), and blood loss was 75 mL (IQR, 50-150 mL). Median hospital stay was 4 days (IQR, 3-5 days). At the final follow-up, treatment success was reported in all patients, who presented grade 0 (n=8, 57.1%) and grade I (n=6, 42.9%) apical prolapse. Dramatic improvements in PFDI-SF 20 scores were noted after RSC (from 39 to 4; P=0.001). Most patients (12 of 13) were satisfied with RSC. An intraoperative complication (sacral venous plexus injury) was reported in 1 patient, and there was no conversion to open surgery. Mesh erosion was not reported. RSC is an efficient and safe surgical option for apical prolapse repair. Most patients were satisfied with RSC. Thus, RSC might be one of the best treatment options for apical prolapse in women.